Zydus Lifesciences has reported a strong financial performance for the year ended March 31, 2026. The company achieved consolidated revenue of INR 271,484 million and a net profit of INR 50,400 million for the full year. The Board of Directors has recommended a final dividend of INR 1 per equity share, subject to shareholder approval at the upcoming Annual General Meeting scheduled for August 11, 2026.
Financial Highlights
For the financial year ended March 31, 2026, Zydus Lifesciences demonstrated significant growth. The company reported consolidated revenue from operations at INR 271,484 million, compared to INR 232,415 million in the previous year. Profit after tax for the full year stood at INR 50,400 million, marking a steady performance over the INR 45,255 million reported in the prior fiscal year.
Quarterly Performance
In the fourth quarter (Q4) ended March 31, 2026, the company recorded consolidated revenue of INR 75,870 million. The net profit for the same quarter was INR 12,725 million. This performance reflects the company’s sustained operational momentum across its business segments throughout the final quarter of the fiscal year.
Strategic Dividend Recommendation
Reflecting confidence in its financial health, the Board of Directors has recommended a final dividend of INR 1 per equity share (at 100% of the face value of INR 1) for the financial year. This recommendation is subject to the approval of shareholders at the company’s Annual General Meeting, which is scheduled to take place on August 11, 2026.
Key Business Developments
The year was marked by significant strategic activity, including the successful acquisition of Amplitude Surgical SAS in France and Comfort Click Limited. Additionally, the company entered into a definitive agreement in May 2026 to acquire Assertio Holdings, Inc., further expanding its global footprint. These strategic moves, alongside investments in U.S.-based biologics manufacturing facilities, underline Zydus Lifesciences’ commitment to long-term growth and diversification.
Source: BSE
